BIRC5 and non-small cell lung carcinoma: This vaccine has mRNAs encoding five NSCLC-related antigens (New York esophageal squamous cell carcinoma-1 (NY-ESO-1), melanoma antigen family C1 and C2, survivin, and trophoblast glycoprotein (5T4)) and was tested in a Phase I/II clinical trial.